Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans

Medical Mycology

Volumn 43, Issue 1, 2005, Pages 27-38

  Uicker, William C ^a   Doyle, Hester A ^b   McCracken, James P ^a   Langlois, Mary ^a   Buchanan, Kent L ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CRYPTOCOCCAL CULTURE FILTRATE ANTIGEN; CYTOKINE; FUNGUS VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFECTION; CELL PROTECTION; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FUNGUS GROWTH; HOST RESISTANCE; IMMUNIZATION; MENINGOENCEPHALITIS; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL;

ANIMALS; BRAIN; CHEMOKINES; CRYPTOCOCCUS NEOFORMANS; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON TYPE II; MENINGITIS, CRYPTOCOCCAL; MICE; MICE, INBRED CBA; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

FILOBASIDIELLA NEOFORMANS;

EID: 13244262681     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780410001731510     Document Type: Article

References (42)

1. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: ASM Press, 1998.
2. Murphy JW. Cell-mediated immunity and medically related fungi. In: Cunningham MW, Fujinami RS (eds). Effects of Microbes on the Immune System. Philadelphia: Lippincott Williams and Wilkins, 2000: 593-621.
3. Aguirre K, Havell EA, Gibson GW, Johnson LL. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun 1995; 63: 1725-1731.
4. + T cell-dependent acquired state of immunity that protects the brain against Cryptococcus neoformans. J Immunol 1994; 152: 2344-2350.
5. Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46: 437-442.
6. + T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect Immun 2000; 68: 456-462.
7. Hoag KA, Street NE, Huffnagle GB, Lipscomb MF. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol 1995; 13: 487-495.
8. Hoag KA, Lipscomb MF, Izzo AA, Street NE. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol 1997; 17: 733-739.
9. + T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol 1994; 55: 35-42.
10. Huffnagle GB, Traynor TR, McDonald RA, et al. Leukocyte recruitment during pulmonary Cryptococcus neoformans infection. Immunopharm 2000; 48: 231-236.
11. Huffnagle GB, Strieter RM, McNeil LK, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J Immunol 1997; 159: 318-327.
12. + T cells during a pulmonary Cryptococcus neoformans infection. J Immunol 1995; 155: 4790-4797.
13. Doyle HA, Murphy JW. MIP-1 alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J Leukoc Biol 1997; 61: 147-155.
14. Murphy JW, Cozad GC. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun 1972; 5: 896-901.
15. Buchanan KL, Murphy JW. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun 1993; 61: 2854-2865.
16. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for the determination of sugars and related substances. Anal Chem 1956; 28: 350-356.
17. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331-10336.
18. Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266: 14147-14150.
19. Szelenyi J. Cytokines and the central nervous system. Brain Res Bull 2001; 54: 329-338.
20. Blasi E, Mazzolla R, Barluzzi R, Mosci P, Bistoni F. Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells. Infect Immun 1994; 62: 3189-3196.
21. Buchanan KL, Murphy JW. Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction. Immunology 1997; 90: 189-197.
22. Kawakami K, Kinjo Y, Uezu K, et al. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J Immunol 2001; 167: 6525-6532.
23. Olszewski MA, Huffnagle GB, McDonald RA, et al. The role of macrophage inflammatory protein-1 alpha/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection. J Immunol 2000; 165: 6429-6436.
24. Huffnagle GB, McNeil LK, McDonald RA, et al. Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol 1999; 163: 4642-4646.
25. Siveke JT, Hamann A. T helper 1 and T helper 2 cells respond differentially to chemokines. J Immunol 1998; 160: 550-554.
26. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-754.
27. Khan IA, MacLean JA, Lee FS, et al. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 2000; 12: 483-494.
28. Sorensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 2001; 8: 665-672.
29. + T cells and viral persistence. J Virol 2002; 76: 2217-2224.
30. Liu MT, Keirstead HS, Lane TE. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol 2001; 167: 4091-4097.
31. + T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2001; 166: 7617-7624.
32. Kutsch O, Oh J, Nath A, Benveniste EN. Induction of the chemokines interleukin-8 and IP-10 by human immunodeficiency virus type 1 tat in astrocytes. J Virol 2000; 74: 9214-9221.
33. Asensio VC, Maier J, Milner R, et al. Interferon-independent, human immunodeficiency virus type 1 gp120- mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J Virol 2001; 75: 7067-7077.
34. Seebach J, Bartholdi D, Frei K, et al. Experimental Listeria meningoencephalitis. Macrophage inflammatory protein-1 alpha and -2 are produced intrathecally and mediate chemotactic activity in cerebrospinal fluid of infected mice. J Immunol 1995; 155: 4367-4375.
35. Chaka W, Verheul AF, Vaishrav VV, et al. Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein. J Immunol 1997; 159: 2979-2985.
36. Delfino D, Cianci L, Lupis E, et al. Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components. Infect Immun 1997; 65: 2454-2456.
37. Vecchiarelli A, Retini C, Pietrella D, et al. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun 1995; 63: 2919-2923.
38. Blasi E, Barluzzi R, Mazzolla R, et al. Biomolecular events involved in anticryptococcal resistance in the brain. Infect Immun 1995; 63: 1218-1222.
39. Lee SC, Dickson DW, Brosnan CF, Casadevall A. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J Exp Med 1994; 180: 365-369.
40. Martin D, Near SL. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol 1995; 61: 241-245.
41. Badovinac V, Mostarica-Stojkovic M, Dinarello CA, Stosic-Grujicic S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol 1998; 85: 87-95.
42. de Jong BA, Huizinga TW, Bollen EL, et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002; 126 172-179.